KalVista Pharmaceuticals, Inc. (KALV)
AI-powered earnings prediction for KalVista Pharmaceuticals, Inc. (KALV).
18.73
-3.10%
USD, about 18 hours ago
Company Overview
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE). The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts.
Sector
Healthcare
Industry
Biotechnology
Website
www.kalvista.comPhone
857 999 0075
Headquarters
200 Crossing Boulevard
Framingham, MA, 01702
United States
Full-Time Employees
275
Key Metrics
Forward P/E
18.16
Price to Book
-361.32
Beta
-0.29
Profit Margin
-223.16%
Gross Margin
25.73%
Return on Equity
N/A
Return on Assets
N/A
Earnings Growth
N/A
Revenue Growth
N/A
Financial Health
Total Cash
$300.21M
Total Debt
$284.21M
Debt to Equity
N/A
Current Ratio
5.58
Operating Cash Flow
$-122431504.00
Analyst Recommendations
Target Price (Mean)
$34.33
Target High
$42.00
Target Low
$22.00
Recommendation
strong_buy
Analyst Coverage
9 Analysts